Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ergot sterioside

An ergosteroid, a single technology, applied in the field of traditional Chinese medicine, can solve problems such as side effects, liver and kidney toxicity, and adverse reactions, and achieve the effects of promoting glucose consumption, low cytotoxicity, and reducing fasting blood sugar levels

Inactive Publication Date: 2011-12-21
SHANGHAI UNIV OF T C M
View PDF2 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs have a certain therapeutic effect on diabetes, but they are also accompanied by many side effects, such as adverse reactions in the digestive tract and certain liver and kidney toxicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ergot sterioside
  • Application of ergot sterioside
  • Application of ergot sterioside

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Take 1 kg of Semen psyllium coarse powder, extract with 4 times the volume of 70% ethanol aqueous solution under reflux for 3 hours, repeat 3 times. The combined extracts were filtered and concentrated to dry solvent.

[0020] The aqueous suspension of the above-mentioned concentrated extract obtained by diluting with water at a weight / volume ratio of 1:3 was extracted with petroleum ether (60-90°C) for several times until the petroleum ether layer was nearly colorless, and the petroleum ether layer was discarded ; The aqueous layer was extracted with saturated n-butanol until the n-butanol layer was nearly colorless, and the n-butanol layers were combined and concentrated under reduced pressure.

[0021] Through silica gel column chromatography, gradient elution was carried out with an ethyl acetate-methanol-water solution system with a volume ratio of 35:1:0.4, and the eluate was collected and concentrated under reduced pressure to obtain crude ergosteroside.

[0022...

Embodiment 2

[0026] HepG2 cells were inoculated in a 96-well plate, and when the cells grew to 60% confluent, they were replaced with a culture medium containing 0.2% bovine serum albumin (BSA) of different concentrations of ergosteroside, and after incubation for 24 hours, the glucose in the culture medium was detected. For the remaining amount, calculate the glucose consumption rate of cells in each well for 24 hours according to the following formula.

[0027] Glucose consumption rate = (the measured value of the experimental well at 0h-the measured value of the experimental well at 24h) / (the measured value of the control well at 0h-the measured value of the control well at 24h)×100%.

[0028] Table 1 Promoting effect of ergosteroid on glucose metabolism in HepG2 cells

[0029]

[0030] Note: Metformin is a positive drug. * P*** P<0.001, compared to control wells.

[0031] It can be seen from Table 1 that ergosteroid can significantly promote the glucose metabolism of HepG2 cells. ...

Embodiment 3

[0033] At the end of the HepG2 cell glucose consumption test, remove the culture medium to be tested, replace it with a culture medium containing 0.5g / LMTT and continue to incubate for 4 hours, then pour out the culture medium, blot dry, add 200 μl dimethyl sulfoxide to each well, and mix. After uniformity, put it on a microplate reader to measure the absorbance at 570nm, and calculate the survival rate of HepG2 cells according to the following formula: cell survival rate=measured value of experimental wells / measured value of control wells×100%.

[0034] Table 2 Toxicity of ergosteroids to HepG2 cells

[0035]

[0036] Note: Metformin is a positive drug. *** P<0.001, compared to control wells.

[0037] It can be seen from Table 2 that compared with the positive control drug metformin, ergosteroside has almost no toxicity to HepG2 cells, showing very good safety.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of ergot sterioside, which refers to the application for preparing diabetes pharmaceutical preparation with only ergot sterioside or composition of ergot sterioside and medical acceptable drug carriers, and develops a novel medical value for ergot sterioside.

Description

technical field [0001] The invention relates to an application of ergosteroside, in particular to a new application of ergosteroside in treating diabetes, and belongs to the technical field of traditional Chinese medicine. Background technique [0002] At present, diabetes has become one of the three major chronic diseases that seriously endanger the health of modern humans. Drugs currently used to treat diabetes mainly include sulfonylureas, glinides, biguanides, thiazolidinedione compounds, and α-glucosidase inhibitors. These drugs have a certain therapeutic effect on diabetes, but they are also accompanied by many side effects, such as adverse reactions in the digestive tract and certain liver and kidney toxicity. Therefore, it is an important task to find new methods with low toxicity and effectiveness in diabetes drug research. [0003] Ergoside (acteoside), its chemical structure is as follows: [0004] [0005] It is a phenylethanol glycoside compound widely dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7028A61P3/10
Inventor 杨莉祁萌王峥涛季光
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com